PT  - JOURNAL ARTICLE
AU  - Deszyński, Piotr
AU  - Młokosiewicz, Jakub
AU  - Volanakis, Adam
AU  - Jaszczyszyn, Igor
AU  - Castellana, Natalie
AU  - Bonissone, Stefano
AU  - Ganesan, Rajkumar
AU  - Krawczyk, Konrad
TI  - INDI – Integrated Nanobody Database for Immunoinformatics
AID  - 10.1101/2021.08.04.21261581
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.08.04.21261581
4099  - http://medrxiv.org/content/early/2021/08/09/2021.08.04.21261581.short
4100  - http://medrxiv.org/content/early/2021/08/09/2021.08.04.21261581.full
AB  - Nanobodies, a subclass of antibodies found in camelids, are a versatile molecular binding scaffold composed of a single polypeptide chain. The small size of nanobodies bestows multiple therapeutic advantages (stability, tumor penetration) with the first therapeutic approval in 2018 cementing the clinical viability of this format. Structured data and sequence information of nanobodies will enable the accelerated clinical development of nanobody-based therapeutics. Though the nanobody sequence and structure data are deposited in the public domain at an accelerating pace, the heterogeneity of sources and lack of standardization hampers reliable harvesting of nanobody information. We address this issue by creating the Integrated Database of Nanobodies for Immunoinformatics (INDI, http://research.naturalantibody.com/nanobodies). INDI collates nanobodies from all the major public outlets of biological sequences: patents, GenBank, next-generation sequencing repositories, structures and scientific publications. We equip INDI with powerful nanobody-specific sequence and text search facilitating access to more than 11 million nanobody sequences. INDI should facilitate development of novel nanobody-specific computational protocols helping to deliver on the therapeutic promise of this drug format.Competing Interest StatementThe authors have declared no competing interest.Funding Statementnot applicableAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:not applicableAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available at http://research.naturalantibody.com/nanobodies http://research.naturalantibody.com/nanobodies